Header Logo

Connection

JAMES COOPER to Immunoconjugates

Back to Details
This is a "connection" page, showing publications JAMES COOPER has written about Immunoconjugates.
JAMES COOPER
Connection Strength
0.711
Immunoconjugates
  1. A Phase I dose-escalation study of DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1) in patients with acute myeloid leukemia. Am J Hematol. 2021 05 01; 96(5):E175-E179.
    View in: PubMed
    Score: 0.711
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.